A scutellaria baicalensis compound and its application
By extracting and purifying purpurin C from purpura, the problem of poor efficacy of existing anti-inflammatory drugs was solved, and effective inhibition of TNF-α, IL-6 and NO was achieved, with potential anti-inflammatory and Anti-cardiovascular disease drugs are used to significantly improve the symptoms of related diseases.
Patent Information
- Application Number
- CN202211712495.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-26
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-12-26
AI Technical Summary
The existing anti-inflammatory drugs have poor efficacy and many side effects. The research on chemical composition extraction and pharmacological activity of Bairuicao is not comprehensive, which limits its clinical application.
New phenolic glycoside compounds (Penolic glycoside C) were extracted from phenolic glycoside, extracted by gradient ethanol-aqueous solution, extracted with petroleum ether and ethyl acetate, silica gel chromatography column, MCI chromatography column and gel chromatography column, etc. Step purification to prepare TNF-α inhibitor, IL-6 inhibitor, NO blocker and anti-inflammatory disease drugs.
Bairuicain C can effectively inhibit tumor necrosis factor and interleukin signaling pathway, reduce the overexpression of related inflammatory mediators, and has potential anti-inflammatory, anti-cardiovascular and anti-autoimmune diseases drugs, significantly improve rheumatoid arthritis, Symptoms of diseases such as ankylosing spondylitis.
Smart Images

Figure CN115974945B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of extraction and application of active ingredients of Chinese herbal medicines, and in particular to a cerebroside compound and application thereof. Background Art
[0002] The Chinese herbal medicine, Thesium chinense Turcz., is derived from the dried whole herb of Thesium chinense Turcz. and its variant, Thesium chinense Turcz. var. longipedunculatum YCChu, of the Santalaceae family. It is mainly distributed in the southern and northern provinces of my country. It was first recorded in the "Compendium of Materia Medica" and is also known as white milk grass, pomegranate, grass sandalwood, and accumulation of medicinal grass. It is cold in nature, pungent and slightly bitter in taste, and enters the spleen and kidney meridians. It has the effects of clearing away heat and detoxifying, tonifying the kidney and astringing essence. It is mainly used to treat wind-heat cold, heatstroke, lung abscess, milk moth, lymph node tuberculosis, breast pain, furuncle, stranguria, jaundice, low back pain, and spermatorrhea.
[0003] Modern studies have shown that spatholobi contains flavonoids, organic acids, alkaloids, polysaccharides, sterols, phenols and mineral elements. Spatholobi is rich in flavonoids, with flavonoid glycosides with kaempferol and kaempferol as the parent nucleus, quercetin, isorhamnetin and its glycosides as the main components. Modern pharmacological studies have shown that spatholobi has antibacterial, anti-inflammatory, analgesic and cytotoxic pharmacological effects. It is clinically used to treat acute mastitis, pneumonia, lung abscess, tonsillitis, upper respiratory tract infection, spermatorrhea, cold, heat stroke and other diseases.
[0004] Inflammation is a pathological process caused by the stimulation of damaging factors in living tissues with vascular systems, and it is also an important factor causing many diseases. At present, clinical anti-inflammatory drugs generally have defects such as poor efficacy and many toxic side effects. Modern studies have shown that kaempferol and its glycoside compounds contained in scutellaria baicalensis, which is known as the "plant antibiotic", have significant anti-inflammatory activity against various inflammatory models caused by carrageenan, xylene, Klebsiella pneumoniae and particulate matter. However, the extraction of chemical components and pharmacological activity of scutellaria baicalensis are still incomplete, so it is necessary to conduct in-depth research to expand its clinical application. Summary of the invention
[0005] In view of this, in order to further study the active ingredients in Herba Lycopodii, the present invention extracts new Herba Lycopodii glycoside compounds from Herba Lycopodii and explores their possible applications.
[0006] In order to solve the above technical problems, the technical solutions adopted in this application are as follows:
[0007] In a first aspect, the present invention provides a cyperoside compound (cyperoside C) having the following structural formula:
[0008]
[0009] Furthermore, the cleroside C is extracted from clerophyllum.
[0010] Furthermore, the method for extracting cleomeside C comprises the following steps:
[0011] Step 1, extracting the herb with ethanol-water solutions of different concentration gradients in sequence, and combining all the extracts;
[0012] Step 2, concentrating the extract to half of its original volume, extracting with petroleum ether and ethyl acetate for multiple times, and combining the organic phases extracted with all polar solvents;
[0013] Step 3, purifying the organic phase sequentially using a silica gel chromatography column, an MCI chromatography column, a gel chromatography column and a preparative liquid chromatography to obtain.
[0014] Furthermore, in the step 1, the herb is extracted with a 95% ethanol-water solution by volume concentration once, an 85% ethanol-water solution by volume concentration once, and a 70% ethanol-water solution by volume concentration twice.
[0015] Furthermore, in step 3, a 200-300 mesh silica gel column is used, and gradient elution is performed with petroleum ether and ethyl acetate in a volume ratio of 3:1, 2:1, and 0:1, respectively.
[0016] Furthermore, in step 3, the MCI chromatographic column is gradient eluted with ethanol-water solutions having volume concentrations of 40%, 60%, 80%, and 100% in sequence.
[0017] Furthermore, in step 3, a Sephadex LH-20 gel chromatography column is used to perform gradient elution with methanol-water solution having a volume concentration of 10%, 40%, 70%, and 100% in sequence.
[0018] In a second aspect, the present invention provides use of the above-mentioned clematiscoside C or a composition containing the above-mentioned clematiscoside C in the preparation of a TNF-α inhibitor.
[0019] In a third aspect, the present invention provides use of the above-mentioned clematiscoside C or a composition containing the above-mentioned clematiscoside C in the preparation of an IL-6 inhibitor.
[0020] In a fourth aspect, the present invention provides use of the above-mentioned clematisin C or a composition containing the above-mentioned clematisin C in the preparation of an NO blocker.
[0021] In a fifth aspect, the present invention provides use of the above-mentioned clematiscoside C or a composition containing the above-mentioned clematiscoside C in the preparation of anti-inflammatory disease drugs.
[0022] The above-mentioned inflammatory diseases include, but are not limited to, rheumatoid arthritis, ankylosing spondylitis, allergic asthma, and diabetes.
[0023] In a sixth aspect, the present invention provides the use of the above-mentioned clematiscoside C or a composition containing the above-mentioned clematiscoside C in the preparation of anti-cardiovascular disease drugs.
[0024] Furthermore, the above-mentioned anti-cardiovascular disease includes but is not limited to atherosclerosis.
[0025] In a seventh aspect, the present invention provides use of the above-mentioned clematiscoside C or a composition containing the above-mentioned clematiscoside C in the preparation of anti-autoimmune disease drugs.
[0026] Furthermore, the above-mentioned anti-autoimmune diseases include but are not limited to systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, and ankylosing spondylitis.
[0027] In an eighth aspect, the present invention provides a drug, which contains the above-mentioned clematisin C or a composition containing the above-mentioned clematisin C, and the drug is one of a TNF-α inhibitor, an IL-6 inhibitor, a NO blocker, an anti-inflammatory disease drug, an anti-cardiovascular disease drug, and an anti-autoimmune disease drug.
[0028] Furthermore, the medicine also includes pharmaceutically acceptable excipients.
[0029] The present invention extracts a new scutellaria glycoside C, which can inhibit tumor necrosis factor and interleukin signaling pathways, reduce the overexpression of related inflammatory mediators, and may be used clinically as a TNF-α inhibitor, IL-6 inhibitor, NO blocker, anti-inflammatory disease drug, anti-cardiovascular disease drug, and anti-autoimmune disease drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 This is the cell activity of cepa glycoside C in Example 2 of the present invention.
[0031] Figure 2 It is the NO inhibition rate of scutellaria baicalensis glycoside C in Example 2 of the present invention.
[0032] Figure 3 This is the effect of scutellaria baicalensis glycoside C on TNF-α content in Example 2 of the present invention.
[0033] Figure 4 This is the effect of scutellaria baicalensis glycoside C on IL-6 content in Example 2 of the present invention.
[0034] Figure 3 and Figure 4 In the data, different numbers of “*” indicate significant differences from the modeling group “0”. DETAILED DESCRIPTION
[0035] In the description of the present invention, it should be noted that, if the specific conditions are not specified in the examples, the experiments were carried out according to conventional conditions or the conditions recommended by the manufacturer. The reagents or instruments used, if the manufacturer is not specified, are all conventional products that can be purchased commercially.
[0036] The present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments, which are intended to explain the present invention rather than to limit it.
[0037] Example 1
[0038] This embodiment provides a method for extracting and purifying clematisin C, which has the following structural formula:
[0039]
[0040] The extraction and purification methods are as follows:
[0041] Step 1, extract the dried whole herb of Herba Lycopodii (500 g) with 95%, 85%, 70%, and 70% ethanol-water solutions with a solid-liquid ratio of 1:4, respectively, once, combine the extracts, and concentrate under reduced pressure to half of the original volume.
[0042] Step 2, extracting four times with petroleum ether and ethyl acetate respectively (the oil-water volume ratio is 2:1) to obtain a petroleum ether extraction phase and an ethyl acetate extraction phase.
[0043] Step 3, passing the ethyl acetate extract through a silica gel column (200-300 mesh), and gradient eluting with petroleum ether and ethyl acetate in a volume ratio of 3:1, 2:1, and 0:1, to obtain 8 fractions (Fr. 1-8).
[0044] Step 4, Fr.8 was separated and purified by MCI chromatography column, and gradient eluted with ethanol-water solution of volume concentration of 40%, 60%, 80%, and 100% in sequence to obtain 6 fractions (Fr.8-1 to Fr.8-6).
[0045] Step 5, Fr.8-6 was separated and purified by Sephadex LH-20 gel column chromatography, and gradient elution was performed with methanol-water solution of volume concentrations of 10%, 40%, 70%, and 100% in sequence to obtain three fractions (Fr.8-6-1 to Fr.8-6-3).
[0046] Step 6, purifying Fr.8-6-1 by preparative liquid chromatography to obtain cyperus scutellariae glycoside C (59 mg), with a yield of 0.118 mg of cyperus scutellariae glycoside C per gram of whole herb, and a purity of more than 99%.
[0047] The relevant structural identification of scutellaria baicalensis glycoside C was carried out, and the specific results are as follows:
[0048] 1) Ceropegol C is an amorphous solid;
[0049] 2) Optical rotation [α] 25 D -26.7 (c0.10, MeOH));
[0050] 3) Infrared identification: IR (KBr) Vmax cm-1 : 3391, 2960, 2923, 2876, 2854, 1606, 1508, 1456, 1383, 1317, 1262, 1229, 1171, 1074, 1030, 983, 895, 862, 803, 774, 747, 718, 623, 579;
[0051] 4) UV(MeOH)λmax nm : 203(0.73);
[0052] 5) 1 H NMR (CD30D, 800 MHz) and 13 C NMR (CD30D, 200 Hz) data are shown in Table 1;
[0053] 6) Mass spectrum FAB-MS (-) m / z: 567 [MH]-, high resolution mass spectrum HRFAB-MS (-) m / z: 567.2658 [MH] - , C 25 H 44 O 14 ).
[0054] Table 1 1 H(800MHz) and 13 C (200 MHz) NMR data (δ ppm) CD3OD
[0055]
[0056]
[0057]
[0058] Example 2
[0059] This example uses a cytotoxicity experiment to verify that the scutellaria glycoside C obtained in Example 1 may have a good anti-inflammatory effect. The specific experiment is as follows:
[0060] 2.1 Cytotoxicity assay
[0061] Raw 264.7 cells were cultured in DMEM complete medium (DMEM medium containing 10% serum, 1% double antibody, v / v) and 5×10 cells were seeded per well in a 96-well plate. 3 cells were placed in a cell culture incubator at 37°C, 5% CO2 for 24 h, and 180 μL of DMEM complete medium containing different final concentrations of clematis glycoside C (0, 6.25, 12.5, 25, 50, 100, 200 μM) was added respectively. Three replicate wells were set for each concentration of clematis glycoside C. After 24 h of drug action, the cell activity at each concentration was detected by CCK-8 method (the average of the three data obtained for each concentration was calculated).
[0062] 2.2 NO content detection
[0063] Raw 264.7 cells were cultured in DEME complete medium (DMEM medium containing 10% serum, 1% double antibody, v / v) and 1×10 cells were seeded per well in a 96-well plate. 4 cells were placed in a cell culture incubator at 37°C, 5% CO2 for 24 h, and 1 mL of complete culture medium containing a final concentration of 1 μg / mL LPS and different gradient final concentrations of lycoside C (0, 3.125, 6.25, 12.5, 25, 50 μM) was added respectively. Three replicate wells were set for each concentration of lycoside C. After 24 h of drug action, the NO content was detected by the Griess NO method (the average of the three data obtained for each concentration was calculated).
[0064] 2.3ELISA detection of IL-6 and TNF-α content
[0065] Raw 264.7 cells were cultured in DEME complete medium (DMEM medium containing 10% serum, 1% double antibody, v / v), and 2.5×10 cells were seeded per well in a 12-well plate. 4 cells were placed in a cell culture incubator at 37°C, 5% CO2 for 24 h, and 180 μμL of complete culture medium containing a final concentration of 1 μg / mL LPS and different gradient final concentrations of lycoside C (0, 6.25, 12.5, 25, 50, 100 μM) were added respectively. Three replicate wells were set for each concentration of lycoside C. After 24 h of drug action, ELISA was used to detect the contents of IL-6 and TNF-α, respectively (the average of the three data obtained for each concentration was calculated).
[0066] 2.4 Results and Discussion
[0067] (1) CCK-8 test results Figure 1 As shown, it was shown that cymoside C had no obvious cytotoxicity at a concentration of 200 μM.
[0068] (2) Griess NO test results are as follows Figure 2 As shown, cymoside C inhibited NO activity IC 50 : 28.6±3.0 (automatically calculated by GraphPad Prism 9.0 software).
[0069] (3) ELISA test results Figure 3 and Figure 4 As shown, Figure 3 In the experiment, for TNF-α, cephaloside C showed obvious drug dependence at 6.25μM. With the increase of drug concentration, the release of TNF-α was significantly inhibited, and the difference was extremely significant at the concentration of 100μM. Figure 4 In the experiment, for IL-6, the extract of clematis glycoside C showed a certain drug dependence from 25 μM, and gradually inhibited the release of IL-6 protein with the increase of drug concentration. Moreover, the inhibitory effect of clematis glycoside C on IL-6 was more obvious than that of TNF-α.
[0070] As an important intercellular communication substance with multiple biological activities, NO plays an important role in the process of inflammation. When inflammation occurs in the body, the protein expression of iNOS is upregulated, thereby inducing the production of a large amount of NO, triggering subsequent related pathological reactions. Ceropegol C can effectively block NO synthesized by iNOS. The main mediators of inflammation include prostaglandins, cytokines, interleukins, and tissue necrosis factor. TNF-α and IL-6 are the main targets of various inflammatory diseases, autoimmune diseases, cardiovascular diseases, etc. (such as: rheumatoid arthritis, ankylosing spondylitis, allergic asthma, diabetes, atherosclerosis, etc.). In the LPS-induced RAW264.7 mouse mononuclear macrophage inflammatory cell model, LPS-mediated inflammatory mediators are mainly TNF-α, IL-6, etc., and clematis glycoside C can effectively inhibit the release of TNF-α and IL-6, indicating that clematis glycoside C can inhibit tumor necrosis factor and interleukin signaling pathways and reduce the overexpression of related inflammatory mediators, thereby hopefully improving the symptoms of diseases such as rheumatoid arthritis, ankylosing spondylitis, allergic asthma, diabetes, obesity, and atherosclerosis to a certain extent.
[0071] In summary, cepa glycoside C can effectively improve the RAW264.7 inflammatory cell model induced by LPS, and may serve as a potential TNF-α inhibitor, IL-6 inhibitor, NO blocker, and potential drug for anti-inflammatory diseases, anti-cardiovascular diseases, and anti-autoimmune diseases.
[0072] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A scutellaria baicalensis glycoside compound, characterized in that: It has the following structural formula: 。 2. The method for extracting the scutellaria baicalensis glycoside compound according to claim 1, characterized in that: The extraction method comprises the following steps: Step 1, drying the whole herb of Herba Lycopodii, extracting it once with 95%, 85%, 70%, and 70% ethanol-water solution with a material-liquid ratio of 1:4, combining the extracts, and concentrating under reduced pressure to half of the original volume; Step 2, extracting four times with petroleum ether and ethyl acetate respectively, with an oil-water volume ratio of 2:1, to obtain a petroleum ether extraction phase and an ethyl acetate extraction phase; Step 3, the ethyl acetate extract phase was passed through a silica gel column with a mesh size of 200-300, and gradient eluted with petroleum ether and ethyl acetate in a volume ratio of 3:1, 2:1, and 0:1, to obtain 8 fractions: Fr. 1-8; Step 4, separating and purifying Fr. 8 by MCI column chromatography, gradient eluting with ethanol-water solution of volume concentrations of 40%, 60%, 80%, and 100% in sequence, to obtain 6 fractions: Fr. 8-1 to Fr. 8-6; Step 5, separating and purifying Fr. 8-6 by Sephadex LH-20 gel column chromatography, gradient eluting with methanol-water solution of 10%, 40%, 70%, and 100% by volume, to obtain three fractions: Fr. 8-6-1 to Fr. 8-6-3; Step 6, purifying Fr. 8-6-1 by preparative liquid chromatography to obtain the gentiana glycoside compound.
3. Use of the scutellaria glycoside compound according to claim 1 or 2 or a composition containing the scutellaria glycoside compound in the preparation of a TNF-α inhibitor.
4. Use of the clematis glycoside compound according to claim 1 or 2 or a composition containing the clematis glycoside compound in the preparation of an IL-6 inhibitor.
5. Use of the scutellaria glycoside compound according to claim 1 or 2 or a composition containing the scutellaria glycoside compound in the preparation of an NO blocker.
6. Use of the scutellaria glycoside compound or a composition containing the scutellaria glycoside compound according to claim 1 or 2 in the preparation of a drug for treating inflammatory diseases, wherein the inflammatory disease is caused by TNF-α and / or IL-6.
7. Use of the scutellaria glycoside compound or a composition containing the scutellaria glycoside compound according to claim 1 or 2 in the preparation of an anti-cardiovascular disease drug, wherein the cardiovascular disease is caused by TNF-α and / or IL-6.
8. Use of the scutellaria glycoside compound or a composition containing the scutellaria glycoside compound according to claim 1 or 2 in the preparation of an anti-autoimmune disease drug, wherein the autoimmune disease is caused by TNF-α and / or IL-6.
9. A drug, characterized in that: The drug includes the scutellaria glycoside compound described in claim 1 or 2 or a composition containing the scutellaria glycoside compound, and the drug is one of a TNF-α inhibitor, an IL-6 inhibitor, an NO blocker, an anti-inflammatory disease drug, an anti-cardiovascular disease drug, and an anti-autoimmune disease drug; wherein the inflammatory disease, the cardiovascular disease, and the autoimmune disease are caused by TNF-α and / or IL-6.
10. The drug according to claim 9, characterized in that: The drug also includes pharmaceutically acceptable excipients.
Citation Information
Patent Citations
Suppressor for melanogenesis and skin external preparation
JP1994092858A
